CAPSULES and ORAL SOLUTION
Rocaltrol (calcitriol) is a synthetic vitamin D analog which is active in the regulation of the absorption of calcium from the gastrointestinal tract and its utilization in the body. Rocaltrol is available as capsules containing 0.25 mcg or 0.5 mcg calcitriol and as an oral solution containing 1 mcg/mL of calcitriol.
Rocaltrol is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (Ccr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of >/= 100 pg/mL is strongly suggestive of secondary hyperparathyroidism.
Rocaltrol is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. In these patients, Rocaltrol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization.
Rocaltrol is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism.
Published Studies Related to Rocaltrol (Calcitriol)
Association of higher plasma vitamin D binding protein and lower free calcitriol
levels with tenofovir disoproxil fumarate use and plasma and intracellular
tenofovir pharmacokinetics: cause of a functional vitamin D deficiency? 
Tenofovir disoproxil fumarate (TDF) causes bone, endocrine, and renal changes by
an unknown mechanism(s)... Separate pharmacokinetic properties may be
associated with distinct TDF toxicities: tenofovir with parathyroid hormone and
altered calcium balance and tenofovir diphosphate with hypophosphatemia and FGF23
Oral Calcitriol for Reduction of Proteinuria in Patients With IgA Nephropathy: A Randomized Controlled Trial. [2011.10.21]
BACKGROUND: Vitamin D has shown efficacy in the reduction of proteinuria in patients with chronic kidney disease. This study aimed to determine the effect of calcitriol on urinary protein excretion in patients with immunoglobulin A (IgA) nephropathy... CONCLUSIONS: The addition of calcitriol to a renin-angiotensin system inhibitor resulted in a safe decrease in proteinuria in patients with IgA nephropathy. Copyright (c) 2011 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. [2011.06.01]
PURPOSE: To compare the efficacy and safety of docetaxel plus high-dose calcitriol (DN-101) to docetaxel plus prednisone in an open-label phase III trial... CONCLUSION: ASCENT treatment was associated with shorter survival than the control. This difference might be due to either weekly docetaxel dosing, which, in a prior study, showed a trend toward inferior survival compared with an every-3-weeks regimen, or DN-101 therapy.
The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol. [2011.05]
BACKGROUND: Lanthanum carbonate and sevelamer carbonate are non-calcium-based phosphate binders used to manage hyperphosphataemia in patients with chronic kidney disease (CKD). Patients with CKD may require intravenous or oral active vitamin D. We investigated the effects of lanthanum carbonate and sevelamer carbonate on the bioavailability of oral calcitriol... CONCLUSIONS: Sevelamer carbonate significantly reduces serum concentrations of exogenous calcitriol when administered concomitantly with oral calcitriol, whereas lanthanum carbonate has no significant effect. This should be considered when treating CKD patients who require phosphate binders and oral vitamin D.
Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients. [2011.03]
AIM: Calcitriol and alfacalcidol are used extensively for the treatment of secondary hyperparathyroidism. Unfortunately, there is limited published data comparing the efficacy and tolerability of both active vitamin D sterols. This study was undertaken to determine whether calcitriol provides a therapeutic advantage to alfacalcidol... CONCLUSION: Alfacalcidol can be used to control secondary hyperparathyroidism at doses of 1.5-2.0 times that of calcitriol. The two drugs are equally efficacious and lead to similar changes in calcium and phosphorus. (c) 2011 The Authors. Nephrology (c) 2011 Asian Pacific Society of Nephrology.
Clinical Trials Related to Rocaltrol (Calcitriol)
Study of DN-101 (Calcitriol) and Docetaxel in Subjects Previously Enrolled in Studies DN101-002 or DN101-004 [Active, not recruiting]
Phase I/II Calcitriol in Lung Cancer [Recruiting]
According to the Cancer Atlas, lung cancer remains the major cancer among the 10. 9 million
new cases of cancer diagnosed annually worldwide. The mortality from lung cancer is greater
than the combined mortality for breast, colon and prostate cancer combined. Most patients
with metastatic non-small-cell lung cancer (NSCLC) are treated with platinum-based
chemotherapy regimens. The drug combination of cisplatin and docetaxel is one of the
commonly used regimens in metastatic NSCLC. Although both drugs are powerful disruptors of
cell growth, positive therapeutic response rates to this therapy remain low for NSCLC
patients, from 25% to 30%. While adding new biologics such as bevacizumab to the current
treatment standard can improve treatment response, median survival for advanced NSCLC
patients receiving this type of treatment remains low at under 12 months. Research studies
have demonstrated that Vitamin D, and it's signaling pathways are important biological
targets in cancer therapeutics. In vitro and in vivo calcitriol (1, 25
dihydroxycholcalciferol) is antiproliferative and potentiates the antitumor effects of
cytotoxic agents (e. g. taxanes, platinum analogues). We have shown that administration of
high doses of calcitriol and cisplatin is feasible and associated with complete tumor
regressions in dogs with spontaneous cancers. Calcitriol has also shown to be synergistic
with docetaxel both in preclinical as well as in a recent phase II clinical trial in
prostate cancer. Based on these results and other supporting data from studies indicating
that calcitriol functions as a potent and well tolerated anti-tumor agent when used in
combination with drugs likes cisplatin and docetaxel, we hypothesize that introducing
calcitriol into treatment regimes for NSCLC patients has the potential to demonstrably
improve treatment response for these patients. The overall goals for conducting this phase
I/II clinical study will be (1) to determine the maximum tolerated dose (MTD) and dose
limiting toxicities (DLT) of calcitriol in combination with cisplatin/docetaxel in patients
with advanced NSCLC, (2) to assess the response rates of patients with advanced NSCLC to the
combination of calcitriol with cisplatin/docetaxel, (3) to evaluate the pharmacokinetics
(PK) of administering calcitriol intravenously at the MTD, and (4) to evaluate correlations
between calcitriol PK and changes on specific coding regions of the gene associated with
Study of High-Dose Pulse Administration DN-101 (Calcitriol) in Patients With Myelodysplastic Syndrome (MDS) [Active, not recruiting]
The purpose of this study is to determine the safety and efficacy of DN-101 (calcitriol) in
patients with myelodysplastic syndrome who are dependent on repeat blood transfusions.
Gene Expression Profile of Breast Cancer Samples After Vitamin D Supplementation [Recruiting]
The purpose of this study is to evaluate whether calcitriol supplementation may reduce tumor
cell proliferation and influence gene expression profile of breast cancer samples from
Study of DN101 and Taxotere in Patients With Advanced Non-Small Cell Lung Cancer [Completed]
This Phase 1/2 clinical trial is a multi-center, open-label study with three main objectives.
The first (Phase 1A) is to determine the maximum-tolerated dose of DN-101 when administered
in combination with Taxotere (docetaxel) every three weeks (closed). The second is to
determine the maximum-tolerated dose of DN-101 when administered weekly in combination with
Taxotere(docetaxel)devery three weeks (open). The third is to evaluate the safety and
objective tumor response rate of the combination in NSCLC. DN-101 doses will be escalated at
three dosing levels. Patients will receive oral DN-101 on day one, followed by intravenous
docetaxel on day two of a 21-day cycle. Treatment cycles will be repeated at the same dose
level each 21 days until disease progression or unacceptable toxicity.
Reports of Suspected Rocaltrol (Calcitriol) Side Effects
Decreased Appetite (6),
Drug Interaction (5),
Cardiac Failure (5),
Hypereosinophilic Syndrome (4),
Renal Failure (4),
Renal Impairment (4),
Productive Cough (3),
Pain (3), more >>
Page last updated: 2014-11-30